Envestnet Asset Management Inc. Sells 2,686 Shares of Biogen Inc. $BIIB

Envestnet Asset Management Inc. lessened its stake in shares of Biogen Inc. (NASDAQ:BIIB) by 4.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 53,390 shares of the biotechnology company’s stock after selling 2,686 shares during the period. Envestnet Asset Management Inc.’s holdings in Biogen were worth $7,479,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently made changes to their positions in the company. Elevation Point Wealth Partners LLC bought a new position in Biogen during the second quarter valued at approximately $25,000. Rothschild Investment LLC raised its holdings in shares of Biogen by 64.7% during the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 88 shares in the last quarter. True Wealth Design LLC boosted its position in shares of Biogen by 62.9% during the 3rd quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 90 shares during the last quarter. NewSquare Capital LLC grew its holdings in shares of Biogen by 134.6% in the second quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 140 shares in the last quarter. Finally, WFA of San Diego LLC purchased a new position in shares of Biogen in the second quarter valued at $32,000. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

Several research firms have commented on BIIB. Robert W. Baird lowered their price objective on shares of Biogen from $255.00 to $250.00 in a research report on Friday, October 31st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Biogen in a report on Monday, February 9th. Piper Sandler lifted their price target on Biogen from $157.00 to $177.00 and gave the stock a “neutral” rating in a research report on Monday, February 9th. Wedbush upped their price objective on Biogen from $178.00 to $187.00 and gave the company a “neutral” rating in a research report on Monday, February 9th. Finally, HC Wainwright raised their price objective on Biogen from $194.00 to $228.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Twelve research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $205.04.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: BIIB091 MS trial reaches completion — Phase 2 readout setup provides a near-term pipeline catalyst that could materially affect investor sentiment if results are favorable. Biogen’s BIIB091 MS Trial Reaches Completion
• Positive Sentiment: New Board chair Maria C. Freire appointed — her experience in biomedical research, drug development and public–private partnerships could refocus partnerships and capital allocation, which investors may view as constructive for strategy and M&A/partnering optionality. New Biogen Chair Freire May Recast Partnerships And Capital Priorities
• Positive Sentiment: Analyst / media coverage highlights improved valuation and strong recent performance — articles noting Biogen as a value / turnaround candidate and highlighting recent gains can attract investors hunting discounted quality names. This supports momentum in the stock. Assessing Biogen (BIIB) Valuation
• Positive Sentiment: Broader ALS therapeutics market growth — a market-research report projects strong CAGR for ALS therapeutics, which is relevant because Biogen has neuro/ALS programs (supporting longer-term revenue upside if clinical progress continues). Global Amyotrophic Lateral Sclerosis Therapeutics Market Size/Share
• Neutral Sentiment: Macro/guidance context and value-stock debate — a piece on “value stocks walking a fine line” highlights valuation risks vs. margin of safety; useful context but not BIIB-specific catalyst. 3 Value Stocks Walking a Fine Line
• Neutral Sentiment: Short-interest data appears noisy/invalid — reported short-interest entries show zero/NaN values and thus offer no reliable signal about positioning or squeeze risk. (Treat with caution.)
• Negative Sentiment: New Alzheimer’s startup Korsana raises $175M — fresh venture capital backing for an Alzheimer’s program (originating at Paragon) increases competition in the amyloid/Alzheimer’s R&D landscape; could pressure long-term franchise assumptions depending on Korsana’s program profile and trial outcomes. An Alzheimer’s startup emerges with $175M in venture backing

Insider Activity at Biogen

In other news, insider Priya Singhal sold 2,660 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This represents a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders own 0.18% of the company’s stock.

Biogen Stock Down 0.0%

Shares of NASDAQ:BIIB opened at $192.03 on Friday. Biogen Inc. has a 1 year low of $110.04 and a 1 year high of $202.41. The business has a 50 day simple moving average of $180.02 and a two-hundred day simple moving average of $161.10. The firm has a market capitalization of $28.18 billion, a PE ratio of 21.80, a price-to-earnings-growth ratio of 1.52 and a beta of 0.16. The company has a debt-to-equity ratio of 0.34, a current ratio of 2.68 and a quick ratio of 2.03.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping the consensus estimate of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The firm had revenue of $2.28 billion for the quarter, compared to the consensus estimate of $2.21 billion. During the same period in the prior year, the business posted $3.44 earnings per share. The company’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. On average, equities analysts predict that Biogen Inc. will post 15.83 EPS for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.